Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Phase 2

Recruiting

• Conditions: APOL1-Mediated Kidney Disease

• Registration Number: NCT06824987
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Detailed Description

This is a Phase 2b study to assess efficacy and safety of AZD2373 involving 3 study treatment arms where participants and study personnel including study investigators are blinded to the assigned treatment.

Participants with 300 mg/g or greater UACR and eGFR ≥ 25mL/min/1.73m2 will be recruited into the study. Participants on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant will be excluded.

All participants will remain in the study on treatment until the last participant has completed 30 weeks of treatment. The treatment duration will be up to minimum of 30 weeks of study treatment.

Approximately 96 participants will be randomized to study intervention (approximately 32 participants in each treatment group).

Study Timeline

• Study First Submitted: 2025-01-24
• Study First Submitted QC: 2025-02-07
• Study First Posted: 2025-02-13
• Status Verified: 2025-03
• Study Start: 2025-03-05
• Last Update Submitted: 2025-03-21
• Last Update Posted: 2025-03-25
• Primary Completion: 2027-08-30
• Study Completion: 2027-08-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

• Age: Male and female participants aged 18 to 65 years, inclusive at the time of informed consent.
• Participants who have high-risk APOL1 genotype (G1/G1; G1/G2; G2/G2). The screening period can be extended if there are delays related to the shipment, handling, or processing of genotype results.
• A geometric mean UACR ≥ 300 mg/g calculated based on the mean of readings taken from 3 FMV urine samples collected on 3 consecutive days. Since the mean will be assessed for eligibility, any of the 3 readings may fall below 300 mg/g.
• eGFR ≥ 25 mL/min/1.73m2.
• Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria

• Participants with diagnosis of Type 1 diabetes mellitus.

• Body Mass Index > 45 kg/m2.

• SBP > 180 mmHg/DBP > 110 mmHg (measured when the participant is considered to be at steady state, and preferably when they have taken their BP medications that same day).

• QTcF > 470 ms.

• Acute coronary syndrome/Acute myocardial infraction +/- coronary intervention with Percutaneous coronary intervention or Coronary artery bypass grafting within 6 months.

• Transient ischaemic attack/ stroke within 3 months.

• High second to third degree AV block or clinically significant sinus node dysfunction untreated with pacemaker.

• A history of ventricular arrhythmias requiring treatment.

• Participants with Type 2 diabetes mellitus must be excluded if ANY of the following conditions are present:

  1. Current or any past use of insulin
  2. Screening Haemoglobin A1c > 8.0%
  3. Receiving more than one oral anti-hyperglycaemic agent (excluding SGLT inhibitors which can be taken in addition to one other oral anti-hyperglycaemic agent).

• Participant on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant.

• History or serologic evidence of autoimmune-mediated glomerular disease including but not limited to: lupus nephritis (positive lupus serology), ANCA associated vasculitis (antineutrophil cytoplasmic antibody), membranous nephropathy (anti-phospholipase A2 receptor antibody or other autoantibody associated with membranous nephropathy), anti-GBM disease (anti-GBM antibody), or IgA nephropathy.

• Another underlying cause of kidney disease that is not associated with APOL1, including but not limited to polycystic kidney disease or, congenital anomalies of the kidney and urinary tract.

• History of a diagnosed coagulopathy, a major unexplained bleeding event, or other high-risk bleeding diathesis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Relative change in Urine Albumin-Creatinine Ratio (UACR)	From Baseline at Week 30	To assess the effect of AZD2373 versus placebo in reducing albuminuria

Secondary Outcome Measures

Name	Time	Method
Relative change in Urine Albumin-Creatinine Ratio (UACR)	From Baseline at the End of Treatment (Until the last participant completes Week 30)	To assess the effect of AZD2373 versus placebo in reducing albuminuria
Relative change in Urine Protein-Creatinine Ratio (UPCR)	From Baseline at the End of Treatment (Until the last participant completes Week 30)	To assess the effect of AZD2373 versus placebo in reducing proteinuria
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)	From Baseline at the End of Treatment (Until the last participant completes Week 30)	To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment
Relative change in eGFR	From Baseline at the End of Treatment (Until the last participant completes Week 30)	To assess pooled AZD2373 doses versus placebo on eGFR change
Incidence of development of ADA and ADA titer (if participants are ADA-positive)	During treatment (up to Week 30) and follow-up (up to 12 weeks)	To evaluate the immunogenicity of AZD2373
Plasma concentration	From Baseline at the End of Treatment (Until the last participant completes Week 30)	To evaluate the PK of AZD2373
Adverse Events (AEs), Serious Adverse Events (SAEs), and Drug Adverse Events (DAEs).	From baseline at the End of Treatment (Until the last participant completes Week 30)	To assess the safety and tolerability of ranging doses of AZD2373. These events will be collected according to the timepoints specified in the schedule of assessments, starting from the time of signing the Informed Consent Form (ICF).

Trial Locations

Locations (1)

Research Site; 🇬🇧 Manchester, United Kingdom